1
|
Ruiu A, Stuppner S, Mone A, Armatura G, Marinello P, Lüthy M, Neri S, Vismara G, Zago M, Ferro F. [An unusual focal finding in breast diagnostics]. Radiologie (Heidelb) 2022; 62:675-678. [PMID: 35913574 DOI: 10.1007/s00117-022-01013-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 04/26/2022] [Indexed: 06/15/2023]
Affiliation(s)
- A Ruiu
- Abteilung für Diagnostische und Interventionelle Radiologie, Antonio Ruiu Regionalkrankenhaus Bozen, 39100, Bozen, Provinz Bozen - Südtirol, Italien.
| | - S Stuppner
- Abteilung für Diagnostische und Interventionelle Radiologie, Antonio Ruiu Regionalkrankenhaus Bozen, 39100, Bozen, Provinz Bozen - Südtirol, Italien
| | - A Mone
- Abteilung für Diagnostische und Interventionelle Radiologie, Antonio Ruiu Regionalkrankenhaus Bozen, 39100, Bozen, Provinz Bozen - Südtirol, Italien
| | - G Armatura
- Abteilung für Chirurgie, KH Bozen, Bozen, Italien
| | - P Marinello
- Abteilung für Chirurgie, KH Bozen, Bozen, Italien
| | - M Lüthy
- Abteilung für Pathologische Anatomie, KH Bozen, Bozen, Italien
| | - S Neri
- Abteilung für Pathologische Anatomie, KH Bozen, Bozen, Italien
| | - G Vismara
- Abteilung für Diagnostische und Interventionelle Radiologie, Antonio Ruiu Regionalkrankenhaus Bozen, 39100, Bozen, Provinz Bozen - Südtirol, Italien
| | - M Zago
- Abteilung für Diagnostische und Interventionelle Radiologie, Antonio Ruiu Regionalkrankenhaus Bozen, 39100, Bozen, Provinz Bozen - Südtirol, Italien
| | - F Ferro
- Abteilung für Diagnostische und Interventionelle Radiologie, Antonio Ruiu Regionalkrankenhaus Bozen, 39100, Bozen, Provinz Bozen - Südtirol, Italien
| |
Collapse
|
2
|
Gregory G, Timmerman J, Lavie D, Borchmann P, Herrera AF, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu Y, Keane C, Kuruvilla J, Palcza J, Pillai P, Marinello P, Johnson NA. P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY. Hemasphere 2022. [PMCID: PMC9428990 DOI: 10.1097/01.hs9.0000847212.00073.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Le D, Diaz L, Kim T, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland P, Cui Y, Leconte P, Marinello P, André T. 432P Pembrolizumab (pembro) for previously treated, microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.953] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
André T, Shiu K, Kim T, Jensen B, Jensen L, Punt C, Smith D, Garcia-Carbonero R, Alcaide García J, Gibbs P, De la Fouchardière C, Rivera Herrero F, Elez E, Bendell J, Le D, Yoshino T, Zhong W, Fogelman D, Marinello P, Diaz L. O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
5
|
Bröckelmann PJ, Müller H, Gillessen S, Yang X, Koeppel L, Pilz V, Marinello P, Kaskel P, Raut M, Fuchs M, Borchmann P, Engert A, Tresckow B. CLINICAL OUTCOMES OF RELAPSED HODGKIN LYMPHOMA PATIENTS AFTER CONTEMPORARY FIRST‐LINE TREATMENT: RESULTS FROM THE GERMAN HODGKIN STUDY GROUP. Hematol Oncol 2021. [DOI: 10.1002/hon.107_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- P. J. Bröckelmann
- Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) University of Cologne Department I of Internal Medicine and German Hodgkin Study Group (GHSG) Cologne Germany
| | - H. Müller
- Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) University of Cologne Department I of Internal Medicine and German Hodgkin Study Group (GHSG) Cologne Germany
| | - S. Gillessen
- Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) University of Cologne Department I of Internal Medicine and German Hodgkin Study Group (GHSG) Cologne Germany
| | - X. Yang
- Merck & Co., Inc. Kenilworth USA
| | | | - V. Pilz
- MSD Sharp & Dohme GmbH Haar Germany
| | | | | | - M. Raut
- Merck & Co., Inc. Kenilworth USA
| | - M. Fuchs
- Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) University of Cologne Department I of Internal Medicine and German Hodgkin Study Group (GHSG) Cologne Germany
| | - P. Borchmann
- Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) University of Cologne Department I of Internal Medicine and German Hodgkin Study Group (GHSG) Cologne Germany
| | - A. Engert
- Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) University of Cologne Department I of Internal Medicine and German Hodgkin Study Group (GHSG) Cologne Germany
| | - B. Tresckow
- University Hospital Essen University of Duisburg‐Essen Department of Hematology and Stem Cell Transplantation West German Cancer Center Essen Germany
| |
Collapse
|
6
|
Yoshino T, Kim T, Yong W, Shiu KK, Jensen BV, Jensen LH, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, Fouchardiere CDL, Rivera F, Elez E, Bendell J, Le D, Yang P, Farooqui M, Marinello P, Diaz L, Andre T. 112P Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
7
|
Kim R, Chaves J, Kavan P, Fakih M, Kortmansky J, Spencer K, Wong L, Tehfe M, Li J, Lee M, Mayo C, Marinello P, Chiorean E. Pembrolizumab (pembro) plus mFOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC): KEYNOTE-651 cohorts B and D. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.085] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Diaz L, Le D, Maio M, Ascierto P, Geva R, Motola-Kuba D, André T, Van Cutsem E, Gottfried M, Elez E, Delord JP, Jäger D, Kim T, Guimbaud R, Yoshino T, Chen M, Norwood K, Marinello P, Marabelle A. Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
9
|
Le D, Kavan P, Kim T, Burge M, Van Cutsem E, Hara H, Boland P, Van Laethem J, Geva R, Taniguchi H, Crocenzi T, Sharma M, Atreya C, Diaz L, Liang L, Marinello P, Dai T, O’Neill B. Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy149.020] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Lonial S, Ribeiro de Oliveira M, Yimer H, Mateos M, Rifkin R, Schjesvold F, San-Miguel J, Ghori R, Marinello P, Jagannath S. KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw525.51] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Michot JM, Armand P, Ding W, Ribrag V, Christian B, Marinello P, Chlosta S, Zhang Y, Shipp M, Zinzani P. KEYNOTE-170: Phase 2 study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw525.49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Mateos M, Blacklock H, Rocafiguera A, Iida S, Jagannath S, Lonial S, Kher U, Farooqui M, Marinello P, San-Miguel J. KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw525.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Michot JM, Armand P, Ding W, Ribrag V, Christian B, Balakumaran A, Marinello P, Chlosta S, Zhang Y, Shipp M, Zinzani P. Pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS): Phase 2 KEYNOTE-170 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.39] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Palumbo A, Mateos MV, Miguel JS, Shah J, Thompson S, Marinello P, Jagannath S. Pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM): randomized, phase 3 KEYNOTE-185 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.35] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Ocio E, Shah J, Jagannath S, Mateos MV, Palumbo A, Kher U, Marinello P, Miguel JS. Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.36] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Abstract
Reverse total shoulder replacement (RTSR) depends on adequate deltoid function for a successful outcome. However, the anterior deltoid and/or axillary nerve may be damaged due to prior procedures or injury. The purpose of this study was to determine the compensatory muscle forces required for scapular plane elevation following RTSR when the anterior deltoid is deficient. The soft tissues were removed from six cadaver shoulders, except for tendon attachments. After implantation of the RTSR, the shoulders were mounted on a custom-made shoulder simulator to determine the mean force in each muscle required to achieve 30° and 60° of scapular plane elevation. Two conditions were tested: 1) Control with an absent supraspinatus and infraspinatus; and 2) Control with anterior deltoid deficiency. Anterior deltoid deficiency resulted in a mean increase of 195% in subscapularis force at 30° when compared with the control (p = 0.02). At 60°, the subscapularis force increased a mean of 82% (p < 0.001) and the middle deltoid force increased a mean of 26% (p = 0.04). Scapular plane elevation may still be possible following an RTSR in the setting of anterior deltoid deficiency. When the anterior deltoid is deficient, there is a compensatory increase in the force required by the subscapularis and middle deltoid. Attempts to preserve the subscapularis, if present, might maximise post-operative function.
Collapse
Affiliation(s)
- L. V. Gulotta
- Hospital For Special Surgery, 535
E 70th Street, New York, New
York 10021, USA
| | - D. Choi
- Hospital For Special Surgery, 535
E 70th Street, New York, New
York 10021, USA
| | - P. Marinello
- Cleveland Clinic, 9500
Euclid Avenue, Cleveland, Ohio
44195, USA
| | - T. Wright
- Hospital For Special Surgery, 535
E 70th Street, New York, New
York 10021, USA
| | - F. A. Cordasco
- Hospital For Special Surgery, 535
E 70th Street, New York, New
York 10021, USA
| | - E. V. Craig
- Hospital For Special Surgery, 535
E 70th Street, New York, New
York 10021, USA
| | - R. F. Warren
- Hospital For Special Surgery, 535
E 70th Street, New York, New
York 10021, USA
| |
Collapse
|
17
|
Macias A, Torres A, Montenegro A, Marinello P, Rodriguez R, Mulens V, Carr A, Mazorra Z, Perez R, Fernandez L. 2110 POSTER Active specific immunotherapy with NGcGM3/ VSSP/ Montanide ISA-51 (CIMAVaxG) vaccine in the treatment of patients with metastatic breast cancer: Results of a randomized phase II clinical trial. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70872-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
18
|
Neninger E, Crombet T, Osorio M, Catala M, Torre A, Leonard I, García B, Marinello P, González G, Lage A. Vaccination with EGF active immunotherapy improves survival in advanced non small cell lung cancer (NSCLC) patients: Interim analysis of a randomized phase II trial. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Neninger
- HHA, Havana, Cuba; CIM, Havana, Cuba; INOR, Havana, Cuba; CIMEQ, Havana, Cuba; HSL, Santa Clara, Cuba; CENCEC, Havana, Cuba
| | - T. Crombet
- HHA, Havana, Cuba; CIM, Havana, Cuba; INOR, Havana, Cuba; CIMEQ, Havana, Cuba; HSL, Santa Clara, Cuba; CENCEC, Havana, Cuba
| | - M. Osorio
- HHA, Havana, Cuba; CIM, Havana, Cuba; INOR, Havana, Cuba; CIMEQ, Havana, Cuba; HSL, Santa Clara, Cuba; CENCEC, Havana, Cuba
| | - M. Catala
- HHA, Havana, Cuba; CIM, Havana, Cuba; INOR, Havana, Cuba; CIMEQ, Havana, Cuba; HSL, Santa Clara, Cuba; CENCEC, Havana, Cuba
| | - A. Torre
- HHA, Havana, Cuba; CIM, Havana, Cuba; INOR, Havana, Cuba; CIMEQ, Havana, Cuba; HSL, Santa Clara, Cuba; CENCEC, Havana, Cuba
| | - I. Leonard
- HHA, Havana, Cuba; CIM, Havana, Cuba; INOR, Havana, Cuba; CIMEQ, Havana, Cuba; HSL, Santa Clara, Cuba; CENCEC, Havana, Cuba
| | - B. García
- HHA, Havana, Cuba; CIM, Havana, Cuba; INOR, Havana, Cuba; CIMEQ, Havana, Cuba; HSL, Santa Clara, Cuba; CENCEC, Havana, Cuba
| | - P. Marinello
- HHA, Havana, Cuba; CIM, Havana, Cuba; INOR, Havana, Cuba; CIMEQ, Havana, Cuba; HSL, Santa Clara, Cuba; CENCEC, Havana, Cuba
| | - G. González
- HHA, Havana, Cuba; CIM, Havana, Cuba; INOR, Havana, Cuba; CIMEQ, Havana, Cuba; HSL, Santa Clara, Cuba; CENCEC, Havana, Cuba
| | - A. Lage
- HHA, Havana, Cuba; CIM, Havana, Cuba; INOR, Havana, Cuba; CIMEQ, Havana, Cuba; HSL, Santa Clara, Cuba; CENCEC, Havana, Cuba
| |
Collapse
|
19
|
Mangiante G, Colucci G, Canepari P, Bassi C, Nicoli N, Casaril A, Marinello P, Signoretto C, Bengmark S. Lactobacillus plantarum reduces infection of pancreatic necrosis in experimental acute pancreatitis. Dig Surg 2001; 18:47-50. [PMID: 11244259 DOI: 10.1159/000050096] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
BACKGROUND Infection is the commonest cause of death in acute pancreatitis. Early reduction of commensal flora (particularly Lactobacillus species) and, at the same time, overgrowth of Enterobacteriaceae, especially Escherichia coli, have recently been described during acute pancreatitis. Lactobacillus plantarum has been shown to be effective in reducing the egress of endotoxin and microbial translocation in several experimental models such as chemically induced hepatitis and ulcerative colitis. AIM The aim of the study was to determine whether L. plantarum 299v (Lp 299v) is capable of effectively reducing microbial translocation in experimental pancreatitis. METHODS Acute pancreatitis was induced by isolation and ligation of the biliopancreatic duct in Lewis rats weighing 250-350 g. The animals were divided into 3 groups: group A, sham operation; group B, induction of pancreatitis and no further treatment, and group C, induction of pancreatitis + daily administration by gavage of a 5-ml/day suspension of Lp 299v at 0.5-1.0 x 10(9) bacteria/ml for 8 days, 4 days before and 4 days after induction of pancreatitis. All animals were sacrificed after 96 h. Histological studies and microbiological analyses were performed. RESULTS At sacrifice, 40/55 animals showed signs of severe pancreatitis. Since acute pancreatitis was the specific disease investigated, only these animals were subjected to further study. In group B, we found pathogenic micro-organisms in the mesenteric lymph nodes in 14/20 animals and in the pancreatic tissue in 10/20. The bacterial flora consisted predominantly of E. coli, Enterococcus faecalis, Pseudomonas and Proteus species. In contrast, when the animals were kept under an 'umbrella' of Lp 299v, growth of E. faecalis or E. coli were detected only in 4/20 mesenteric lymph node cultures and in 3/20 pancreatic tissue cultures. CONCLUSIONS Lp 299v is effective in reducing microbial translocation in experimental pancreatitis. Treatment with probiotic bacteria seems to be a promising alternative to antibiotic therapy.
Collapse
Affiliation(s)
- G Mangiante
- Department of Surgery, University of Verona, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Marinello P, Montresor E, Iacono C, Bortolasi L, Acerbi A, Facci E, Martignoni G, Brunelli M, Mainente M, Serio G. Long-term results of aggressive surgical treatment of primary and recurrent retroperitoneal liposarcomas. Chir Ital 2001; 53:149-57. [PMID: 11396061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
The aim of this study was to establish the role of surgery in the treatment of retroperitoneal liposarcomas. Data concerning 28 patients submitted to surgery for retroperitoneal liposarcoma in our department over the period from 1972 to 1999 were reviewed retrospectively and analysed. Seventy-four operations were performed; in 54% of the operations it was necessary to resect contiguous organs (kidney 60%, colon 50%, adrenal gland 35%). In 89%, grossly curative resection was achieved at the first operation; 20 patients had at least one local recurrence after first operation (median time interval: 22 months). The mean follow-up was 80 months; median survival time was 51 months and 5-year actuarial survival time 51%. Patients with low-grade liposarcoma showed a statistically significant improvement (P < 0.001) in median survival (153 months) versus those with medium- (37 months) and high-grade sarcomas (8 months). At present surgery is still the treatment of choice in the treatment of primary and recurrent liposarcoma; in the case of low-grade liposarcomas especially, an aggressive surgical approach can result in long-term survival.
Collapse
Affiliation(s)
- P Marinello
- Department of Surgery and Gastroenterology, G.B. Rossi Hospital University of Verona, P.le A.L. Scuro, 37134 Verona
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Montresor E, Procacci C, Guarise A, Minniti S, Bortolasi L, Nifosì F, Marinello P, Mainente M, Puchetti V. Strangulated traumatic hernia of the diaphragm. A report of two cases. Chir Ital 1999; 51:471-6. [PMID: 10742899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
The herniation of abdominal viscera in the thorax can immediately follow diaphragmatic rupture or be delayed even years after the injury. The herniated viscera can strangulate; this consequence may lead to a dangerous misdiagnosis which could be lethal for the patient. Radiological procedures, serial chest X-ray studies, CT and MRI scans are mandatory to confirm diagnosis. The insertion of a naso-gastric tube is a very helpful method in ruling out hypertensive pneumothorax in the presence of an air-fluid level in the thorax. We report 2 cases of strangulated traumatic hernia of the diaphragm occurring just a few hours (case 1) and 18 months (case 2) after the trauma. During thoracotomy, a rupture of the left diaphragmatic cupola was demonstrated with herniation of the stomach in case 1, the stomach, spleen and transverse colon in case 2. No postoperative mortality or morbidity were detected.
Collapse
Affiliation(s)
- E Montresor
- Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Università degli Studi di Verona
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Mangiante G, Canepari P, Colucci G, Marinello P, Signoretto C, Nicoli N, Bengmark S. [A probiotic as an antagonist of bacterial translocation in experimental pancreatitis]. Chir Ital 1999; 51:221-6. [PMID: 10793768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Infection is the most common cause of death in acute pancreatitis. Earlier studies have demonstrated that early enteral nutrition decreases microbial translocation, upregulates the immune function and reduces septic complications and mortality. Lactobacillus plantarum (Lp) has been shown to be effective in reducing egress of endotoxin and microbial strain that showed very high adherence power to gut mucosa. We adopted a model of acute pancreatitis induced by isolation and ligation of biliopancreatic duct in adult Lewis rats. Three groups were studied: A. control group (sham operation); B. induced pancreatitis, no further treatment; C. Induced pancreatitis + gavage with 5 ml/day of a suspension of Lp 299 v in a dose of 0.5-1.0 x 10(9)/ml during 4 days before and 4 days after induction of pancreatitis. All animals were sacrificed after 96 hours. Histological studies and microbiological analyses were performed. Forty out of 55 animals showed signs of severe pancreatitis on sacrifice after 96 hours. Only these animals were further studied. In group A, we found only 1/20 bacteria in mesenteric nodes (MN). Pathogenic microrganisms were found in the non-treated group in MN in 14/20 and in the pancreatic tissue in 10/20. In contrast, when kept on an umbrella of Lp 299 v, only 4/20 animals demonstrated growth of enteric bacteria in MN and 3/20 in pancreatic tissue. All of these results showed a significant reduction of infection in the treated groups. In our model, Lp 299 v is effective in preventing microbial translocation in experimental pancreatitis. Treatment with probiotic bacteria, such as Lactobacillus spp, seems to be a promising alternative as problems with antibiotic-resistant bacteria seem to accumulate.
Collapse
Affiliation(s)
- G Mangiante
- Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Università degli Studi di Verona
| | | | | | | | | | | | | |
Collapse
|
23
|
González G, Crombet T, Catalá M, Mirabal V, Hernández JC, González Y, Marinello P, Guillén G, Lage A. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998; 9:431-5. [PMID: 9636835 DOI: 10.1023/a:1008261031034] [Citation(s) in RCA: 122] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND There is evidence of a relationship between epidermal growth factor (EGF) and tumor cell proliferation, such as the overexpression of EGF receptor (EGF-R) in different human tumors, which makes this system an interesting target for cancer treatment. Up to now, passive immunotherapy with monoclonal antibodies against the EGF-R has been assayed in clinics. Our approach consists of active immunotherapy with human EGF (hu-EGF). We conducted a pilot clinical trial to define the safety, toxicity and immunogenicity of vaccination with hu-EGF coupled to a carrier protein. PATIENTS AND METHODS Ten patients with histologically-proven malignant carcinomas (colon, lung, stomach and prostate) in advanced clinical stages were enrolled. Patients were immunized twice (on days 0 and 15) with hu-EGF linked to either tetanic toxoid (TT, five patients) or P64K Neisseria Meningitidis recombinant protein (P64k, five patients), intradermically, using aluminium hydroxyde as adjuvant. RESULTS In both groups 60% of patients developed anti-EGF antibody titers without evidence of toxicity. Secondary reactions were very mild, limited to erythema and itching at the site of injection, which disappeared without medication. CONCLUSIONS We conclude that the proposed vaccination with hu-EGF was well tolerated and that antibody titers against self EGF were developed. The results of this trial may be useful in the design of new clinical trials with higher dose immunization protocols and using more effective adjuvants.
Collapse
Affiliation(s)
- G González
- Center of Molecular Immunology, Havana, Cuba.
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Mangiante GL, Colombari R, Portuese A, Bortolasi L, Marinello P, Colucci G, Montresor E, Serio GE. Inflammatory pseudotumor of the liver: case report and review of the literature. G Chir 1997; 18:417-20. [PMID: 9471218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Inflammatory pseudotumors of the liver (IPL) are extremely rare focal lesions of the parenchyma. Up to now, the ethology of IPL has not been completely understood. Usually the clinical presentation is with fever, chills, hepatic mass. The fine needle biopsy shows a large amount of inflammatory cells, while the most common imaging techniques are not specific and do not reach a definitive preoperative diagnosis between a benign and a malignant tumor. From the examination of the Literature, the Authors found a mortality rate of 40% among patients treated by antibiotic therapy, while surgical procedures were successful in all but one case. Moreover, in Authors' case, successfully treated by hepatic resection, the preoperative diagnostic procedures were not helpful in differential diagnosis with a malignant lesion. For these reasons, the Authors believe surgery is the best therapeutic choice in case of a suspected IPL without an early clinical resolution after antibiotic therapy.
Collapse
Affiliation(s)
- G L Mangiante
- Dipartimento di Scienze Chirurgiche, Cattedra di Chirurgia Generale, Chirurgia C, Università degli Studi di Verona
| | | | | | | | | | | | | | | |
Collapse
|